Silicosis

Laser Photonics’ CleanTech Laser Cleaning Systems Streamline Car Restoration

Retrieved on: 
Tuesday, February 13, 2024
Hardware, Automotive Manufacturing, Manufacturing, Technology, Robotics, Other Automotive, Performance & Special Interest, General Automotive, Other Manufacturing, Other Technology, Aftermarket, Automotive, Machinery, Steel, Machine Tools, Metalworking & Metallurgy, Engineering, Clean technology, Corrosion, Silicosis, Common

Laser Photonics Corporation , a leading global developer of industrial laser systems for laser cleaning and other material applications, highlights a key application for its CleanTech laser systems.

Key Points: 
  • Laser Photonics Corporation , a leading global developer of industrial laser systems for laser cleaning and other material applications, highlights a key application for its CleanTech laser systems.
  • Laser cleaning can increase the quality and accuracy of rust cleaning during restoration.
  • Another application for CleanTech laser systems during car restoration is surface preparation, which plays a vital role in the automotive painting process.
  • For more information about the CleanTech line of laser cleaning systems, please visit https://www.laserphotonics.com or contact our sales department at [email protected] .

Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S.

Retrieved on: 
Tuesday, August 29, 2023
Patent, Human, Ocean Biomedical, NASH, RI, United States Patent and Trademark Office, Lupus, Asbestosis, Pulmonary fibrosis, Fibrosis, HPS, EPA, Connective tissue, Silicosis, Hermansky–Pudlak syndrome, Fatty liver disease, IPF, Alcoholic liver disease, Idiopathic pulmonary fibrosis, Rheumatoid arthritis, Scleroderma, Pharmaceutical industry, MD

Providence, RI, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that the United States Patent and Trademark Office has issued a patent covering Ocean’s anti-Chitinase 1 small molecule candidate.

Key Points: 
  • Patent granted for use in IPF, HPS, alcoholic liver disease, nonalcoholic steatohepatitis (NASH), and scleroderma.
  • Providence, RI, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA ) announced today that the United States Patent and Trademark Office has issued a patent covering Ocean’s anti-Chitinase 1 small molecule candidate.
  • Targeted diseases include alcoholic liver disease, idiopathic pulmonary fibrosis (IPF), scleroderma, nonalcoholic steatohepatitis (NASH), and Hermansky-Pudlak Syndrome (HPS), a rare disease that currently has no known treatments.
  • Ocean’s approach has shown an 85%–90% reduction in collagen accumulation in four different IPF and HPS pulmonary fibrosis animal models.

Global Industrial Dust Collector Market to Reach $12.2 Billion by 2031, Registering a CAGR of 4.4%

Retrieved on: 
Tuesday, August 22, 2023
COPD, Asthma, Health and Safety Executive, Atmosphere, Disability, Workplace, Safety, HSE, Lung cancer, Control of Substances Hazardous to Health Regulations 2002, Substance, Chronic obstructive pulmonary disease, Silicosis, Control, Mortality, COSHH, Environment, Organization, Video game, Personal protective equipment, Poultry farming, Health

The industrial dust collector market was valued at $7,871.2 million in 2021, and is projected to reach $12,223.2 million by 2031, registering a CAGR of 4.4% from 2022 to 2031.

Key Points: 
  • The industrial dust collector market was valued at $7,871.2 million in 2021, and is projected to reach $12,223.2 million by 2031, registering a CAGR of 4.4% from 2022 to 2031.
  • Some of the most common types of dust collectors are cyclone dust collector, bughouse dust collector, cartridge dust collector, electrostatic precipitator and wet scrubber.
  • The global industrial dust collector market forecast analysis from 2022 to 2031 is included in the report.
  • The key market players within industrial dust collector market are profiled in this report and their strategies are analyzed thoroughly, which help understand the competitive outlook of the industrial dust collector industry.

Incremental environmental change can be as hazardous as a sudden shock – managing these ‘slow-burning’ risks is vital

Retrieved on: 
Thursday, August 10, 2023
Food, Carcinogen, Atmosphere, Garden, Cancer, Risk management, Risk assessment, Asbestosis, Resource Management Act 1991, Silicosis, Soil, Resource management, Risk, Asbestos, Water, City, Landslide, Climate change, Health, Increment, Environment, Legislation, Agriculture, Environmental remediation

Although risk assessment and management procedures try to account for hazards in a systematic way, they often overlook risks arising from incremental and seemingly insignificant environmental changes.

Key Points: 
  • Although risk assessment and management procedures try to account for hazards in a systematic way, they often overlook risks arising from incremental and seemingly insignificant environmental changes.
  • But over time, or when aggregated, incremental changes can lead to significant impacts on human health and wellbeing.
  • Incremental changes in our environments can evade regulation if their effects are slow-burning, uncertain, or there is a time lag between cause and effect.
  • However, given the requirement for significant change, it is hard to see how these provisions could be used proactively to manage incremental changes.

Respirable mineral dust

    • They can gradually accumulate in the lungs, causing diseases such as pleural changes, silicosis and asbestosis, even cancer.
    • However, the causes of frequent but low-level exposures to mineral dust have often escaped regulation.

Cumulative effects of incremental loss of green space

    • Our built environment of impermeable surfaces is slowly encroaching on urban green spaces and gardens.
    • Instead, consent applications are assessed on their individual impacts and there are few mechanisms to sufficiently assess and manage aggregate and cumulative effects.

What needs to happen

    • If we continue to only consider the immediate and local effects from individual actions, we are not able to protect people from future cumulative consequences.
    • Marc Tadaki receives funding from Te Apārangi Royal Society of New Zealand and the Ministry of Business, Innovation and Employment.
    • Martin Brook receives funding from Royal Society Te Apārangi, Toka Tū Ake EQC, and Ministry of Business, Innovation and Employment.
    • He is a chartered geologist (CGeol) with the Geological Society of London, and a member of Engineering New Zealand (MEngNZ).

Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Breakthrough Pulmonary Fibrosis Treatments Issued to Scientific Co-founder Dr. Jack A. Elias.

Retrieved on: 
Thursday, April 20, 2023
Yale University, Patent, Kidney failure, Ocean Biomedical, Idiopathic pulmonary fibrosis, Therapy, Prevalence, NASH, Critical Care Medicine (journal), RI, United States Patent and Trademark Office, University, Survival, Dean, Yale New Haven Hospital, Research, Asbestosis, Pulmonary fibrosis, Pharmacotherapy, Fibrosis, HPS, Science, Silicosis, Patient, Chandos Chair of Medicine and Anatomy, Hermansky–Pudlak syndrome, Brown University, IPF, Alcoholic liver disease, IND, Biology, Scleroderma, Pharmaceutical industry, Medicine

This patent allowance covers pulmonary fibrosis caused by multiple conditions including: idiopathic pulmonary fibrosis (IPF), genetic pulmonary fibrosis such as Hermansky-Pudlak Syndrome (HPS), chemotherapy and radiation-induced pulmonary fibrosis, and exposure-induced interstitial lung diseases including asbestosis and silicosis.

Key Points: 
  • This patent allowance covers pulmonary fibrosis caused by multiple conditions including: idiopathic pulmonary fibrosis (IPF), genetic pulmonary fibrosis such as Hermansky-Pudlak Syndrome (HPS), chemotherapy and radiation-induced pulmonary fibrosis, and exposure-induced interstitial lung diseases including asbestosis and silicosis.
  • A Notice of Allowance is issued after the USPTO examines a patent application and determines that the applicant should be granted a patent from the application.
  • Ocean Biomedical anticipates that a patent will be issued by the USPTO from Dr. Elias’ application in the coming months.
  • In four pulmonary fibrosis animal models, Ocean Biomedical’s OCF-203 has shown an 85% – 90% reduction in collagen accumulation.

Caesarstone Announces Date for Third Quarter 2022 Results

Retrieved on: 
Wednesday, October 26, 2022
Interior Design, Residential Building & Real Estate, Manufacturing, Commercial Building & Real Estate, Construction & Property, Other Manufacturing, U.S. Securities and Exchange Commission, Pinterest, Investor relations, SEC, Form 20-F, Webcast, Transport, GHG, Conference, YouTube, ESG, NASDAQ, CSTE, International use of the U.S. dollar, Twitter, Instagram, Annual report, Security (finance), Private Securities Litigation Reform Act, Goal, Company, Major, Forward-looking statement, Heart, COVID-19, Silicosis, Risk, Risk management, Facebook, Caesarstone

Caesarstone Ltd. (NASDAQ: CSTE), a leading developer and manufacturer of high-quality engineered surfaces, today announced that it will release its earnings results for the third quarter ended September 30, 2022 on Wednesday, November 9, 2022 before the market opens.

Key Points: 
  • Caesarstone Ltd. (NASDAQ: CSTE), a leading developer and manufacturer of high-quality engineered surfaces, today announced that it will release its earnings results for the third quarter ended September 30, 2022 on Wednesday, November 9, 2022 before the market opens.
  • ET to discuss the results, followed by a question and answer session for the investment community.
  • Upon dialing in, please request to join the Caesarstone Third Quarter 2022 Earnings Conference Call.
  • Actual results may differ materially from those projected as a result of certain risks and uncertainties, both known or unknown.

BioLink Life Sciences, Charak Foundation and KARE Biosciences Announce contract for developing a novel treatment of COVID pneumonia and prevention of long COVID

Retrieved on: 
Wednesday, October 5, 2022
Time-invariant system, D2, Atherosclerosis, Sepsis, United States Department of Health and Human Services, Breathe Me, Biomedical Advanced Research and Development Authority, Disease, Hospital, Sickle cell disease, Coagulation, Indapamide, Pandemic, Spironolactone, Development, Human services, Pulmonary hypertension, Pneumonia, Severe acute respiratory syndrome coronavirus 2, Education, COVID, Allergic rhinitis, Medicine, Patient, Thrombosis, Open philanthropy (doctrine), Ogletree, Degenerative disease, Immune system, Administration, Company, PGD2, Health, Hypoxemia, Department, Blood, A2, Biolink zones, Eplerenone, Prostaglandin D2, Thromboxane A2, Philanthropy, COVID-19, Mouth, Silicosis, Pharmaceutical industry, Ramatroban

BioLink's $750,000 contract from BARDA complements a multimillion dollar grant from Open Philanthropy to the Charak Foundation.

Key Points: 
  • BioLink's $750,000 contract from BARDA complements a multimillion dollar grant from Open Philanthropy to the Charak Foundation.
  • Ramatroban has been approved and used in Japan for over 20 years for treatment of allergic rhinitis by twice daily oral administration.
  • BioLink Life Sciences is a North Carolina based clinical research company that develops novel, proprietary pharmaceutical products via multiple regulatory pathways.
  • KARE Biosciences is also developing a novel, antihypertensive combination of indapamide, the best-in-class thiazide-like diuretic, in combination with a mineralocorticoid receptor antagonist (spironolactone or eplerenone).

Caesarstone to Attend Zelman 2022 Virtual Housing Summit

Retrieved on: 
Tuesday, September 20, 2022
Interior Design, Residential Building & Real Estate, Manufacturing, Commercial Building & Real Estate, Construction & Property, Other Manufacturing, Risk, GHG, CFO, ESG, COVID-19, CSTE, Major, Company, Forward-looking statement, U.S. Securities and Exchange Commission, CEO, Goal, Transport, Private Securities Litigation Reform Act, NASDAQ, Heart, Security (finance), SEC, Annual report, International use of the U.S. dollar, Form 20-F, Silicosis, Risk management, Caesarstone

Caesarstone Ltd. (NASDAQ: CSTE), a leading developer and manufacturer of high-quality engineered surfaces, today announced that Yuval Dagim, CEO, and Nahum Trost, CFO, will attend the Zelman 2022 Virtual Housing Summit on Wednesday, September 21, 2022.

Key Points: 
  • Caesarstone Ltd. (NASDAQ: CSTE), a leading developer and manufacturer of high-quality engineered surfaces, today announced that Yuval Dagim, CEO, and Nahum Trost, CFO, will attend the Zelman 2022 Virtual Housing Summit on Wednesday, September 21, 2022.
  • Caesarstone is a global leader of premium surfaces, specializing in countertops that create dynamic spaces of inspiration in the heart of the home.
  • Established in 1987, its multi-material portfolio of over 100 colors combines the companys innovative technology with its powerful design passion.
  • Spearheading high-quality, sustainable surfaces, Caesarstone delivers functional resilience with timeless beauty, for a vast range of applications, including kitchen countertops, bathroom vanities, and more, for indoor and outdoor spaces.

Aerobotix Partners With FerRobotics to Develop First-of-Its-Kind End-of-Arm-Tool Automated Sander for Flammable Dust

Retrieved on: 
Wednesday, September 14, 2022
Technology, Other Defense, Engineering, Automotive Manufacturing, Aerospace, Manufacturing, Machinery, Hardware, Robotics, Defense, Time, Safety, Human, Aircraft, Risk, Dust, Urinary tract infection, Industry, Degenerative disease, AOK, Automation, CEO, International Labour Organization, Injury, Dangerous, Workplace, Technology, Robotics, Death, EOAT, Multimedia, Silicosis, Atmosphere, 3D printing, Poultry

View the full release here: https://www.businesswire.com/news/home/20220914005260/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220914005260/en/
    The new C2D1-rated End of Arm Tool (EOAT) automated sander from Aerobotix and FerRobotics.
  • The invention of a force-compliant C2D1-rated automated sander, with integral dust collection, virtually eliminates the risk of occupationally acquired respiratory infections.
  • Aerobotix remains committed to improving safety in the aerospace and defense industries, said Josh Tuttle, business development manager at Aerobotix.
  • Creating this first C2D1 EOAT sander of its kind with Aerobotix is a proud achievement for FerRobotics.

Caesarstone to Attend the Jefferies Industrials Conference

Retrieved on: 
Thursday, August 4, 2022
Construction & Property, Interior Design, U.S. Securities and Exchange Commission, CEO, Forward-looking statement, SEC, Security (finance), Silicosis, ESG, International use of the U.S. dollar, COVID-19, Company, Transport, CSTE, Major, Risk, NASDAQ, GHG, Goal, Private Securities Litigation Reform Act, Heart, Form 20-F, Annual report, Conference, Risk management, Caesarstone

Caesarstone Ltd. (NASDAQ: CSTE), a leading developer and manufacturer of high-quality engineered surfaces, today announced that Yuval Dagim, CEO, will attend the Jefferies Industrials Conference in New York, NY on Tuesday, August 9, 2022.

Key Points: 
  • Caesarstone Ltd. (NASDAQ: CSTE), a leading developer and manufacturer of high-quality engineered surfaces, today announced that Yuval Dagim, CEO, will attend the Jefferies Industrials Conference in New York, NY on Tuesday, August 9, 2022.
  • Caesarstone is a global leader of premium surfaces, specializing in countertops that create dynamic spaces of inspiration in the heart of the home.
  • Established in 1987, its multi-material portfolio of over 100 colors combines the companys innovative technology with its powerful design passion.
  • Spearheading high-quality, sustainable surfaces, Caesarstone delivers functional resilience with timeless beauty, for a vast range of applications, including kitchen countertops, bathroom vanities, and more, for indoor and outdoor spaces.